Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families
- 145 Downloads
The relationship between renal cell cancer (RCC) and hematologic malignancy (HM) in the same individual has been reported for more than 20 years, and is noted in SEER database studies. Family histories suggest a familial association as well. This study evaluates the occurrence of renal cell cancer and hematologic malignancies in individual patients and families, and the occurrence of age-of-onset anticipation among generations. Family history data from our familial patient registry, including more than 700 pedigrees of familial hematologic malignancies, and 700 patients with renal cell cancer, were reviewed. Twenty-six patients with a personal history of both RCC and HM are reported. Seventy four patients with RCC are noted to have 95 family members with HM. Consistent with past reports, there was male predominance among the patients with both diseases (71 %), and among the RCC patients’ relatives with HM (57 %). Also consistent was a predominance of lymphoid malignancies in those with both diseases (92 %) and in the HMs among family members of RCC patients (79 %). The majority (95 %) of HM relatives were first or second degree relatives of the patient with RCC. Thirty of 34 parent/child pairs demonstrated age of onset anticipation in which the child developed either disease at a younger age than the parent. The co-occurrence of RCC and HM in the same patient has been shown to be significantly greater than expected. Families also appear to have an increased association. The appearance of anticipation suggests that genetic factors may be significant in this association of RCC and HM.
KeywordsRenal cell cancer Familial hematologic malignancies Lymphoma
Supported in part by Cancer Research Foundation of New York, Chappaqua NY; Children’s Leukemia Research Association, Garden City, New York; Long Island League Against Cancer (L.I.L.A.C.), New York; Jewish Community Trust, New York.
All authors have contributed to this manuscript, by collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of the manuscript. In addition, Drs Wiernik and Dutcher have provided study conception and design and have contributed subjects for the study.
Compliance with ethical standards
Conflict of interest
Drs. Varella and Chintapatla have no conflicts to disclose. Dr. Wiernik participates in speakers bureau and advisory boards for Novartis and Celgene. Dr. Dutcher participates in speakers bureau and advisory boards for Prometheus, Novartis and Pfizer, and is a member of data safety and monitoring boards for Bristol-Myers-Squibb, Tracon, and PrECOG.
The study protocol was approved by the institutional review board. All participants gave informed consent. All procedures performed were in accordance with ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 7.Dutcher JP, Wiernik PH (2011) Renal cell carcinoma and hematologic malignancy in the same patients. J Invest Med 59:634 (abst)Google Scholar
- 23.Hwang SM, Kuyava JM, Grande JP, Swetz KM (2015) Metastatic renal cell carcinoma mimicking diverticulitis in a patient with chronic lymphocytic leukaemia. BMJ Case Rep bcr2014206161Google Scholar
- 31.Prosvic P, Dulicek P, Odrazka K, Navratilová J, Morávek P, Veselský Z (2003) Asynchronous occurrence of three neoplastic diseases: chronic B-cell lymphatic leukemia, renal carcinoma and prostatic carcinoma. Rozhi Chir 82:583–586Google Scholar
- 49.Varella L, Chintapatla R, Wiernik PH, Dutcher JP (2012) Association of renal cell carcinoma and hematologic malignancies. Br J Urol 110(Suppl 2):10–11 (abst)Google Scholar
- 50.Chintapatla R, Varella L, Wiernik P, Rusciano V, Dutcher JP (2012) Association of renal cell carcinoma and B-cell hematologic malignancy. Blood 120(Suppl) (epub) (Abst 5086)Google Scholar
- 51.Varella L, Chintapatla R, Wiernik PH, Rusciano V, Dutcher JP (2013) Association of renal cell and hematologic malignancies. J Clin Oncol 31(suppl):204 (abst 449)Google Scholar
- 53.NCI SEER Stat Facts 2010–2012. SEER.cancer.gov/statfacts/html
- 58.Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J (1991) Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. Proc Natl Acad Sci USA 88:2864–2868CrossRefPubMedPubMedCentralGoogle Scholar
- 59.Whaley JM, Naglich J, Gelbert L, Lamiell JM, Green JS, Collins D, Neumann HP, Laidlaw J, Li FP (1994) Germ-line mutations in the von Hippel–Lindau tumor suppressor gene are similar to somatic von Hippel–Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092–1102PubMedPubMedCentralGoogle Scholar
- 60.Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM (1996) Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1242:201–210PubMedGoogle Scholar
- 61.Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, De Costa L, Pérot C, Ribraq V, Patte C, Wiels J, Bernheim A (2009) High resolution genome-wide analysis of chromosomal alterations in Burkitt’s lymphoma. PLoS ONE 4:e7089CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Farley N, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimemez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middleton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie J, Dahia PL, Eng C, Linehan WM, Brugarolas J (2013) A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11(9):1061–1071CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Wang SS, Gu YF, Wolff N, Stefanius K, Christie A, Day A, Hammer RE, Xie XJ, Rakheja D, Pedrosa L, Carroll T, McKay RM, Kapur P, Brugarolas J (2014) Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci USA 111:16538–16543CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Schmidt LS, Junker K, Weirich G, Glenn G, Choyke P, Lubensky L, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan WM, Zbar B (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719–1722PubMedGoogle Scholar
- 66.Schmidt LS, Junker K, Nakagawa N, Kinjerski T, Weirich G, Miller M, Lubensky L, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richards S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations in the MET protooncogene in papillary renal carcinomas. Oncogene 18:2343–2350CrossRefPubMedGoogle Scholar
- 68.Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner M, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman M, Linehan WM, Zbar B, Schmidt LS (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with Birt–Hogg–Dube syndrome. Cancer Cell 2:157–164CrossRefPubMedGoogle Scholar
- 74.Papadavid E, Korkolopoulou P, Levidou G, Saetta AA, Papadaki T, Siakantaris M, Nikolaou V, Okonomidi A, Chatziandreou I, Marinos L, Kollalexi A, Stratigos A, Rigopoulos D, Psyrri A, Patsouris E, Antoniou C (2014) In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features. Exp Dermatol 12:931–933CrossRefGoogle Scholar
- 76.Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollbert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dimhofer S, Lenz P, Hummel M, Tzankov A, Lenz O (2013) PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:12420–12425CrossRefPubMedPubMedCentralGoogle Scholar
- 77.Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon, or the combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and poor risk features. N Engl J Med 356:2271–2281CrossRefPubMedGoogle Scholar
- 78.Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomized, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMedGoogle Scholar
- 85.Etkind PR, Stewart AFR, Dorai T, Purcell DJ, Wiernik PH (2004) Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both breast tumors and non-Hodgkin’s lymphomas of individual patients diagnosed with both malignancies. Clin Cancer Res 10:5656–5664CrossRefPubMedGoogle Scholar
- 88.Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ, Das KM (2014) Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 20:5461–5473CrossRefPubMedPubMedCentralGoogle Scholar
- 94.Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T (2009) Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus. J Clin Oncol 27:453–459CrossRefPubMedPubMedCentralGoogle Scholar
- 99.Stratton KL, Schrader KA, Manschreck C, Rau-Murthy R, Corines M, Dutcher J, Wiernik P, Palomba L, Portlock C, Murali R, Klein RJ, Coleman J, Stadler Z, Offit K, Vijai J (2013) Renal cell carcinoma and non-Hodgkin’s lymphoma: genomic approaches to identification of shared susceptibility. Proc Soc Urol Oncol (abst)Google Scholar